Antiretroviral therapy coverage for PMTCT in Middle East, North Africa, Afghanistan & Pakistan (excluding high income)
Middle East, North Africa, Afghanistan & Pakistan (excluding high income): Antiretroviral therapy coverage for PMTCT was 20.1% in 2024. ◆ Volatile
Antiretroviral therapy coverage for PMTCT in Middle East, North Africa, Afghanistan & Pakistan (excluding high income), 2000–2024
Source: UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Measured in % of pregnant women living with HIV.
Analysis
In 2024, antiretroviral therapy coverage for pmtct in Middle East, North Africa, Afghanistan & Pakistan (excluding high income) stood at 20.1%.
Compared with earlier readings it is up 25.1% on the previous year and up 45.9% over ten years.
Over the whole period, antiretroviral therapy coverage for pmtct in Middle East, North Africa, Afghanistan & Pakistan (excluding high income) peaked at 24.6% in 2019 and was at its lowest, 0.0%, in 2000.
The series is highly variable year to year, so single readings are best treated with caution.
Antiretroviral therapy coverage for PMTCT in Middle East, North Africa, Afghanistan & Pakistan (excluding high income), year by year
| Year | % of pregnant women living with HIV | Change |
|---|---|---|
| 2000 | 0.0% | — |
| 2001 | 0.0% | — |
| 2002 | 0.1% | — |
| 2003 | 1.0% | +1079.4% |
| 2004 | 1.3% | +34.7% |
| 2005 | 2.2% | +72.3% |
| 2006 | 4.7% | +113.4% |
| 2007 | 5.1% | +9.1% |
| 2008 | 8.0% | +56.1% |
| 2009 | 8.9% | +10.4% |
| 2010 | 12.7% | +42.9% |
| 2011 | 13.1% | +3.5% |
| 2012 | 13.3% | +0.9% |
| 2013 | 17.5% | +32.1% |
| 2014 | 13.7% | -21.5% |
| 2015 | 15.8% | +15.1% |
| 2016 | 19.0% | +20.1% |
| 2017 | 18.4% | -3.0% |
| 2018 | 22.2% | +20.6% |
| 2019 | 24.6% | +10.7% |
| 2020 | 12.5% | -49.3% |
| 2021 | 20.8% | +66.7% |
| 2022 | 18.2% | -12.6% |
| 2023 | 16.0% | -11.9% |
| 2024 | 20.1% | +25.1% |
Biggest year-on-year movements
Years where Antiretroviral therapy coverage for PMTCT in Middle East, North Africa, Afghanistan & Pakistan (excluding high income) changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.
| Year | Change | From | To |
|---|---|---|---|
| 2003 | +1079.4% | 0.1% | 1.0% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 3.1% | 0.0% | 8.9% | 10 |
| 2010s | 17.0% | 12.7% | 24.6% | 10 |
| 2020s | 17.5% | 12.5% | 20.8% | 5 |
Countries ranked near Middle East, North Africa, Afghanistan & Pakistan (excluding high income)
More health data for Middle East, North Africa, Afghanistan & Pakistan (excluding high income)
- Population ages 35-39, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 40-44, male, annual growth rate 3.11 % change on previous year (2025)
- Population ages 40-44, female, per capita 0.0305 units per person (2025)
- Population ages 40-44, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 40-44, female, annual growth rate 3.21 % change on previous year (2025)
- Population ages 35-39, male, per capita 0.0351 units per person (2025)
- Population ages 35-39, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 35-39, male, annual growth rate 1.51 % change on previous year (2025)
- Population ages 35-39, female, per capita 0.0341 units per person (2025)
- Population ages 30-34, female, annual growth rate 0.4849 % change on previous year (2025)
All data for Middle East, North Africa, Afghanistan & Pakistan (excluding high income) →
Frequently asked questions
- What is antiretroviral therapy coverage for pmtct in Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
- Antiretroviral therapy coverage for pmtct in Middle East, North Africa, Afghanistan & Pakistan (excluding high income) was 20.1% in 2024, according to UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS).
- What is the highest antiretroviral therapy coverage for pmtct recorded in Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
- The highest recorded value was 24.6% in 2019.
- What is the lowest antiretroviral therapy coverage for pmtct recorded in Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
- The lowest recorded value was 0.0% in 2000.
- How does Middle East, North Africa, Afghanistan & Pakistan (excluding high income) rank for antiretroviral therapy coverage for pmtct?
- Middle East, North Africa, Afghanistan & Pakistan (excluding high income) ranks 14th out of 15 groups with data for 2024.
- Is antiretroviral therapy coverage for pmtct rising or falling in Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
- Over the last ten years it is up 45.9%. The long-run trend across the full record is volatile.
- Where does this Middle East, North Africa, Afghanistan & Pakistan (excluding high income) data come from?
- The figures come from UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as part of Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Percentage of pregnant women with HIV who receive antiretroviral medicine for prevention of mother-to-child transmission (PMTCT).